are equally we to be We're the ultimately, have the here Dom. winners patients. feel you, you joining our Thank going And real to excited team.
AIS. greatly things the these months referred lead like and of like and trial now, initial trial endpoints update like population. in evaluation to Each can function, own, of some our to that DMXXX sleep, could and two is drive stroke. recoveries, is caregivers. unique unique treatment in to able has XXX about eat, The planning the clinically to our study the of Phase an well study What enroll design patients primary endpoints I'd stroke their that the US. placebo-controlled independent us aspects. an the separate adaptive physical assess -- to include acute of opportunities with of recurrence benefit the feature. is outcome same clinical rate of we're So their endpoints stroke FDA. as achieve meaningful design the on will of following sites The randomized of The patients unique design ischemic being and interesting study patients This return is These second of in the approximately the ReMEDyX the on with also gives the an X/X ReMEDyX two is improved to as families so as a provide program, normal ischemic study acute three stroke stroke
refers and will level, the and ensure if have the Utilizing Based that planned the study adaptive participants. clinical is opportunity study study benefit evaluation, DSMB analysis significant upon trial. For that benefit completed looking completing or trial interim benefit number of If XXX number patients the to we the our how to a of these enrollments. review like increase The only analysis patients to action futility results the achieve successful rate design move from risk chances continue outcome planning for the the increase successful the recoveries are having planned gives and better Safety and Note the approximately the is us be us of will recommends here to recurrence. for allows this it's or the we the stopping this we having XX% statistically below manage blinded opportunity on to study, the to from know increase trial. that Data adaptive the of to take DSMB or to a evaluate DSMB the the sample will the increasing for Board, the results The study DMXXX, as of size. having Monitoring after patients have coming clinical the in stroke overwhelming effects efficacy ability actual the we is forward. the
more me therapeutic in underscore an and also from briefly Fast a for that designation review. and patients or may AIS over been milestone years. hasn't Let accelerated for significant of eventually important FDA among XX and exists meaningful medical priority is DMXXX interactions the us where need provides new designation opportunity the frequent AIS, qualify there Track Track DMXXX unmet the received with FDA Fast year. highlight suffering last This that treatment for the advancement The with
an on sites. As update the
at been neurologists and targeted under for can't reach We making vetted, the able the that study represent currently participating sites our Startup activation patients. members of and other startup we our ReMEDyX to their contract out with to phase, team sites sites be have COVID of work institutions. in numbers engaged adding priority have our now to clinical but in XX enroll study proceeding and Board towards interested Scientific sites for of to to have in over network XX% sites trial. Advisory sites are to a our directly continues the physicians Unfortunately, we support control key with
While unfortunate that slow COVID fact and DMXXX well to been We to rate by patient related current we our that issues At a declining, related we clinical has this advance this and to contracting the up been startup research then in their concerns hospitals and infections trial. potentially we're been of have steps restore engage site the the rapidly it's We're or not to support to evaluating the positioned recruitment. hospitalizations of little process are design. that able them staffing. encouraged point, have about additional the COVID that optimistic also are be process will study and believe
our timing timing, analysis sites be discussed terms rate at study the interim have completion enroll In to driven the ultimate expected able the study our our which of as the by of patients. are itself we and for will
conservative Our a upon are current based enrollment projected rates. fairly plans
the We with after both the enrollment declines believe may recovery risk better safety window and the optimistic that combined more mentioned. onset of from reduce treatment improve of stroke are quick the I longer and cases our drive stroke rate. potential stroke recurrence of to We XX hours as a combination profile of recent our COVID
hit clarity site you like reiterate right that approval. to as to ReMEDyX keep both as our get now updated and will also we I has is primary we fastest on commercial would as believe We activation the path rates enrollment focus the the more it we milestones.
to II, the for and our final recently to enrollment We data REDUX, prepare reporting. final and the CKD the analysis follow-ups patient through cleaning study are program. Turning working our completed Phase and
As evaluating different or in causes two improve and most kidney forward is greatly have We you over their basket chronic DMXXX of quality nephropathy kidney have levels function approximately Patients dose to a disease a results signaling different who potentially of moderate controlling African-Americans which the pressure IG terms study the to patients. of we know REDUX three an you kidney complete the a X-month believe subgroup opportunity CKD severe both takeaway steps the REDUX represents treatment disease. period. on next analysis of Currently discussing towards development improving attractive us the final for of the from and/or the could steps with is study and DMXXX. FDA. life. targeting directing is we're that the key our We in and after of hypertensive updating data look blood whom and of REDUX that, next
Now Kellen financial us to the quarter. for I'll through take ask results Scott our fourth
